Literature DB >> 16425388

Characteristics of patients with columnar-lined Barrett's esophagus and risk factors for progression to esophageal adenocarcinoma.

Kamal E Bani-Hani1, Bayan K Bani-Hani, Iain G Martin.   

Abstract

AIM: To determine the risk factors for the development of esophageal adenocarcinoma in these patients with columnar-lined esophagus (CLE).
METHODS: Data collected retrospectively on 597 consecutive patients diagnosed at endoscopy and histology to have CLE at Leeds General Infirmary between 1984 and 1995 were analyzed. Factors evaluated included age, sex, length of columnar segment, smoking, and drinking habits, history of non-steroidal ingestion, presence of endoscopic esophagitis, ulceration or benign strictures and presence of Helicobacter pylori in esophageal biopsies. Univariate and multivariate analyses were performed to identify risk factors for the development of adenocarcinoma.
RESULTS: Forty-four patients presented or developed esophageal adenocarcinoma during follow-up. Independent risk factors for the development of adenocarcinoma in patients with CLE were males (OR 5.12, 95%CI 2.04-12.84, P=0.0005), and benign esophageal stricture (OR 4.37, 95%CI 2.02-9.45, P=0.0002). Male subjects and patients who developed benign esophageal stricture constituted 86% (n=38) of all patients who presented or developed esophageal adenocarcinoma. The presence of esophagitis was associated with a significant reduction in the development of esophageal carcinoma (OR 0.28, 95%CI 0.13-0.57, P=0.0006). No other clinical characteristics differentiate between the non-malignant and malignant group.
CONCLUSION: In patients with CLE, endoscopic surveillance for the early detection of adenocarcinoma may be restricted to male subjects, as well as patients who develop benign esophageal strictures.

Entities:  

Mesh:

Year:  2005        PMID: 16425388      PMCID: PMC4725040          DOI: 10.3748/wjg.v11.i43.6807

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  64 in total

1.  Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings.

Authors:  A J Cameron; A R Zinsmeister; D J Ballard; J A Carney
Journal:  Gastroenterology       Date:  1990-10       Impact factor: 22.682

2.  Association between body mass and adenocarcinoma of the esophagus and gastric cardia.

Authors:  J Lagergren; R Bergström; O Nyrén
Journal:  Ann Intern Med       Date:  1999-06-01       Impact factor: 25.391

3.  Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.

Authors:  A P Weston; A S Badr; R S Hassanein
Journal:  Am J Gastroenterol       Date:  1999-12       Impact factor: 10.864

4.  Adenocarcinoma and Barrett's esophagus. An overrated risk?

Authors:  S J Spechler; A H Robbins; H B Rubins; M E Vincent; T Heeren; W G Doos; T Colton; E M Schimmel
Journal:  Gastroenterology       Date:  1984-10       Impact factor: 22.682

5.  Adenocarcinoma of the esophagogastric junction and Barrett's esophagus.

Authors:  A J Cameron; C T Lomboy; M Pera; H A Carpenter
Journal:  Gastroenterology       Date:  1995-11       Impact factor: 22.682

6.  Adenocarcinoma complicating columnar epithelium-lined (Barrett's) esophagus.

Authors:  R C Haggitt; J Tryzelaar; F H Ellis; H Colcher
Journal:  Am J Clin Pathol       Date:  1978-07       Impact factor: 2.493

7.  Adenocarcinoma in Barrett's oesophagus: an overrated risk.

Authors:  A H Van der Veen; J Dees; J D Blankensteijn; M Van Blankenstein
Journal:  Gut       Date:  1989-01       Impact factor: 23.059

8.  Barrett's oesophagus.

Authors:  J F Bartlesman; W Hameeteman; G N Tÿtgat
Journal:  Eur J Cancer Prev       Date:  1992-06       Impact factor: 2.497

9.  Barrett's oesophagus: a clinical study of 52 patients.

Authors:  B T Cooper; G O Barbezat
Journal:  Q J Med       Date:  1987-02

10.  Population based cohort study of the association between alcohol intake and cancer of the upper digestive tract.

Authors:  M Grønbaek; U Becker; D Johansen; H Tønnesen; G Jensen; T I Sørensen
Journal:  BMJ       Date:  1998-09-26
View more
  10 in total

Review 1.  Magnitude of Missed Esophageal Adenocarcinoma After Barrett's Esophagus Diagnosis: A Systematic Review and Meta-analysis.

Authors:  Kavel Visrodia; Siddharth Singh; Rajesh Krishnamoorthi; David A Ahlquist; Kenneth K Wang; Prasad G Iyer; David A Katzka
Journal:  Gastroenterology       Date:  2015-11-24       Impact factor: 22.682

Review 2.  Clinical implications of molecular changes in pediatric Barrett's esophagus.

Authors:  Licia Pensabene; Marta C Cohen; Michael Thomson
Journal:  Curr Gastroenterol Rep       Date:  2012-06

3.  Cigarette smoking and the risk of Barrett's esophagus.

Authors:  Ai Kubo; T R Levin; Gladys Block; Gregory Rumore; Charles P Quesenberry; Patricia Buffler; Douglas A Corley
Journal:  Cancer Causes Control       Date:  2008-10-14       Impact factor: 2.506

Review 4.  Predictors of progression in Barrett's esophagus: current knowledge and future directions.

Authors:  Ganapathy A Prasad; Ajay Bansal; Prateek Sharma; Kenneth K Wang
Journal:  Am J Gastroenterol       Date:  2010-01-26       Impact factor: 10.864

5.  Increasing expression of hypoxia-inducible proteins in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence.

Authors:  E A Griffiths; S A Pritchard; S M McGrath; H R Valentine; P M Price; I M Welch; C M L West
Journal:  Br J Cancer       Date:  2007-04-17       Impact factor: 7.640

6.  Managing Barrett's esophagus with radiofrequency ablation.

Authors:  Junichi Akiyama; Andrew Roorda; George Triadafilopoulos
Journal:  Gastroenterol Rep (Oxf)       Date:  2013-03-26

7.  Alcohol consumption and the neoplastic progression in Barrett's esophagus: a systematic review and meta-analysis.

Authors:  Zhifeng Lou; Haibo Xing; Da Li
Journal:  PLoS One       Date:  2014-10-09       Impact factor: 3.240

8.  Microsatellite instability in metaplasia-dysplasia-adenocarcinoma sequence of Barrett esophagus: a retrospective study.

Authors:  Pave Markoš; Iva Brčić; Luka Brčić; Jasminka Jakić-Razumović; Roland Pulanić
Journal:  Croat Med J       Date:  2018-06-30       Impact factor: 1.351

9.  Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett's esophagus: a meta-analysis.

Authors:  S Zhang; X-Q Zhang; X-W Ding; R-K Yang; S-L Huang; F Kastelein; M Bruno; X-J Yu; D Zhou; X-P Zou
Journal:  Br J Cancer       Date:  2014-03-20       Impact factor: 7.640

10.  Barrett's esophagus surveillance in a prospective Dutch multi-center community-based cohort of 985 patients demonstrates low risk of neoplastic progression.

Authors:  Esther Klaver; Angela Bureo Gonzalez; Nahid Mostafavi; Rosalie Mallant-Hent; Lucas C Duits; Bert Baak; Clarisse J M Böhmer; Arnoud H A M van Oijen; Ton Naber; Pieter Scholten; Sybren L Meijer; Jacques J G H M Bergman; Roos E Pouw
Journal:  United European Gastroenterol J       Date:  2021-07-06       Impact factor: 4.623

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.